跳至主要内容
临床试验/ISRCTN79120387
ISRCTN79120387已完成未知

A randomised, single-masked, phase IV pilot study of the efficacy and safety of adjunctive intravitreal Avastin® (bevacizumab) in the prevention of early postoperative vitreous haemorrhage following diabetic vitrectomy

Moorfields Eye Hospital NHS Foundation Trust (UK)0 个研究点目标入组 30 人开始时间: 2008年1月11日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. A diagnosis of non-clearing or recurrent vitreous haemorrhage due to proliferative diabetic retinopathy - indicated for Pars Plana Vitrectomy (PPV)
  • 2. Visual acuity better than perception of light
  • 3. Patient fit for and agreed to have PPV
  • 4. >20 years old

排除标准

  • 1. Previous vitrectomy
  • 2. Ocular and systemic contra-indication for vitrectomy
  • 3. Unfit for local or general anaesthesia
  • 4. Inability to obtain visual acuity, fundus imaging or fluorescein angiogram
  • 5. Reduced potential visual acuity due to corneal or optic nerve disease, or amblyopia
  • 6. Previous intravitreal Avastin® injection in either eye
  • 7. Inability to give informed consent
  • 8. Inability to comply with follow-up visit and investigation
  • 9. Women of childbearing age
  • 10. Recent (<1 month) acute myocardial infarct, Transient Ischaemic Attack (TIA) or stroke

研究者

发起方
Moorfields Eye Hospital NHS Foundation Trust (UK)

相似试验

进行中(未招募)
不适用
A randomised, single-masked, Phase IV pilot study of the efficacy and safety of adjunctive intravitreal Avastin® (bevacizumab) in the prevention of early postoperative vitreous haemorrhage following diabetic vitrectomy - Intravitreal Avastin® in diabetic vitrectomyVitreous haemorrhage secondary to proliferative diabetic retinopathy
EUCTR2007-000780-21-GBMoorfields Eye Hospital
进行中(未招募)
不适用
Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selective anti-VEGF (Macugen) or Pan anti-VEGF (Avastin). - ND
EUCTR2008-001600-23-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
尚未招募
不适用
Randomised comparison of the Ambu® Laryngeal Mask with the Laryngeal Mask Airway UniqueTM during anaesthesia in spontaneously breathing adult patientsAirway maintenance during anaesthesiaAnaesthesiology - Other anaesthesiologyRespiratory -
ACTRN12606000429550Royal Melbourne Hospital - Department of Anaesthesia and Pain Management100
进行中(未招募)
1 期
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)'s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV's Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlers
EUCTR2019-002988-10-ITGLAXOSMITHKLINE BIOLOGICALS500
进行中(未招募)
1 期
A study to evaluate immunogenicity and safety of GlaxoSmithKline (GSK)’s Infanrix hexa vaccine (DTPa HBV IPV/Hib) versus MCM Vaccine BV’s Vaxelis vaccine (DTaP5 HBV IPV Hib) in healthy infants and toddlersHealthy volunteers [Primary and booster immunization of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (Hib)]MedDRA version: 21.1Level: LLTClassification code 10054187Term: Polio immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10069593Term: Pertussis immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054180Term: Diphtheria immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: LLTClassification code 10054183Term: Tetanus immunizationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2019-002988-10-DEGlaxoSmithKline Biologicals SA500